These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12198933)

  • 21. [The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
    Olsen J; Gundgaard J; Borris LC
    Ugeskr Laeger; 2005 May; 167(21):2273-9. PubMed ID: 15962854
    [No Abstract]   [Full Text] [Related]  

  • 22. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Medical experts groups and choice of medications. A fair prioritization process guarantees the reliability of the choice of medications].
    Garpenby P
    Lakartidningen; 2004 Aug; 101(32-33):2480-2, 2484. PubMed ID: 15346621
    [No Abstract]   [Full Text] [Related]  

  • 24. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial.
    von Scheele B; Peña B; Wong J; Niculescu L
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii53-9. PubMed ID: 14585918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cost-effectiveness analysis of a peak flow-based asthma education and self-management plan in a high-cost population.
    de Asis ML; Greene R
    J Asthma; 2004 Aug; 41(5):559-65. PubMed ID: 15360065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of health economic information by reimbursement authorities.
    Drummond MF
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cost savings by right choice of drugs. Decision making models for "good prescription" are presented].
    Hoffmann M
    Lakartidningen; 1997 Feb; 94(9):733-6, 739. PubMed ID: 9091750
    [No Abstract]   [Full Text] [Related]  

  • 29. An economic model to reduce the cost of chemotherapy for gynecologic cancer.
    Jacobs VR; Thoedtmann J; Brunner B; Kiechle M
    Int J Fertil Womens Med; 2004; 49(6):274-7. PubMed ID: 15751266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of recombinant human copper zinc superoxide dismutase administered at birth to premature infants.
    McBride JA; Parad RB; Davis JM; Zheng Z; Zupancic JA;
    J Perinatol; 2009 May; 29(5):364-71. PubMed ID: 19225525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
    Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
    Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Policies concerning pharmaceutical prices and reimbursement in Mexico, Organization for Co-operation and Economic Development. 2007].
    Moïse P; Docteur E
    Salud Publica Mex; 2008; 50 Suppl 4():S504-10. PubMed ID: 19082262
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
    Carrington M; Stewart S
    Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
    Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
    Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of decentralised drug-budgets in Sweden - a survey of physicians' attitudes towards costs and cost-effectiveness.
    Jansson S; Anell A
    Health Policy; 2006 May; 76(3):299-311. PubMed ID: 16046026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone].
    Eklund K; Grip L; Israelsson B; Levin LA; Lindahl B; Wallentin L
    Lakartidningen; 2008 May 7-13; 105(19):1408-9; discussion 1409. PubMed ID: 18574983
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.